The clinical course of 201 patients with malignant non-Hodgkin-lymphomas was analysed according to the Kiel classification. The five-year survival rate of 133 patients with lymphomas of low grade malignancy was 63% in comparison to 23% out of 68 patients with lymphomas of high grade malignancy. Radio- and chemotherapy were used in a different way. Patients with centrocytic-centroblastic lymphomas had the best porgnosis, which was not influenced by the stage of the disease. The poorest prognosis was observered in patients with lymphoblastic lymphomas. These results support the importance of a classification of malignant non-Hodgkin-lymphomas which is not only based on morphological criteria.

Eighty‐two patients with Hodgkin's disease (H.D.) and 40 patients with Multiple Myeloma (M.M.) were HL‐A typed. The results were compared with those of 255 healthy individuals of the same geographical area. In both diseases W18 (4cr) ‐ belonging to the 4c‐complex ‐ was significantly increased.

Samples of the urine of 10 myeloma patients with proteinuria were examined by SDS-PAGE. Light chain proteins of Bence Jones (B.J.) type were excreted by 7 patients as monomer (m.w. 20--26.5 x 10(3) Dalton, by 2 patients as a mixture of monomer and dimer and by one patient as dimer. By two-dimensional electrophoresis in SDS-PAG and subsequent electrophoresis in agarose containing kappa and lambda chain specific antibodies the immunological identity of monomeric and dimeric B.J. protein of one patient has been shown. The two-dimensional analysis has been proven a valuable procedure in cases with the excretion of complete monoclonal protein and B.J. protein at the same time.